Menopause and mood

Clinical Obstetrics and Gynecology

Volumn 47, Issue 3, 2004, Pages 576-591

  Soares, Claudio N ^a   Joffe, Hadine ^a   Steiner, Meir ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIDEPRESSANT AGENT; CITALOPRAM; CONJUGATED ESTROGEN; MIRTAZAPINE; PAROXETINE; PRASTERONE; PROGESTERONE; VENLAFAXINE;

ADULT; AGED; BRAIN FUNCTION; COGNITION; CONFERENCE PAPER; CULTURAL FACTOR; DEMENTIA; DEPRESSION; EXPERIENCE; FEMALE; HORMONAL REGULATION; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSE; MOOD; MOOD DISORDER; QUALITY OF LIFE; SLEEP PATTERN; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MOOD DISORDERS;

EID: 4644285477     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000129918.00756.d5     Document Type: Conference Paper

References (139)

1. Census. USBot. Women's History Month. Vol. 2004. Available at: http://www.census. gov/Press-Release/www/2004/cb04-ff04. pdf.
2. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351-358.
3. Harlow BL, Wise LA, Otto MW, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2003;60:29-36.
4. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61:62-70.
5. Kaufert PA, Gilbert P, Tate R. Defining menopausal status: the impact of longitudinal data. Maturitas. 1987;9:217-226.
6. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas. 2002;42:195-200.
7. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab. 1985;61:627-632.
8. Haas S, Walsh B, Evans S, et al. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol. 1988;71:671-676.
9. Polo-Kantola P, Erkkola R, Helenius H, et al. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol. 1998;178:1002-1009.
10. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-420.
11. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
12. Purdie DW, Empson JA, Crichton C, et al. Hormone replacement therapy, sleep quality and psychological wellbeing. Br J Obstet Gynaecol. 1995;102:735-739.
13. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
14. McKinlay SM. The normal menopause transition: an overview. Maturitas. 1996;23:137-145.
15. Soules M, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76:874-878.
16. Leibenluft E. Foreword. In: Leibenluft E, ed. Gender Differences in Mood and Anxiety Disorders. Washington, D.C.: American Psychiatric Press; 1999.
17. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
18. Steiner M. Female-specific mood disorders. Clin Obstet Gynecol. 1992;35:599-611.
19. Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med. 1993;23:157-162.
20. Born L, Steiner M. The relationship between menarche and depression in adolescence. CNS Spectrums. 2001;6:126-138.
21. Soares CN, Cohen LS, Otto MW, et al. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Womens Health Gend Based Med. 2001;10:873-878.
22. Harlow BL, Cohen LS, Otto MW, et al. Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 1999;56:418-424.
23. Porter M, Penney GC, Russell D, et al. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol. 1996;103:1025-1028.
24. Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry. 1998;6:121-132.
25. Soares CN, Cohen LS. The perimenopause and mood disturbance. CNS Spectrums. 2001;6:167-174.
26. Kaufert PA, Gelbert P, Tate R. The Manitoba Project: a reexamination of the link between menopause and depression. Maturitas. 1992;14:143-155.
27. Schmidt PJ, Roca CA, Bloch M, et al. The perimenopause and affective disorders. Seminars Reprod Endo. 1997;15:91-100.
28. Avis NE, McKinlay SM. A longitudinal analysis of women's attitudes towards menopause: results from the Massachusetts Women's Health Study. Maturitas. 1991;13:65-79.
29. Hunter M. The south-east Eglbad longitudinal study of the climacteric and postmenopause. Maturitas. 1992;14:117-126.
30. Stovall TG, Summitt RL Jr, Lipscomb GH, et al. Reproductive health, use of estrogen and experience of symptoms in perimenopausal women: a population-based study. Obstet Gynecol. 1995;85:30-32.
31. Ballinger CB, Browning MC, Smith AH. Hormone profiles and psychological symptoms in peri-menopausal women. Maturitas. 1987;9:235-251.
32. Fink G, Sumner BE, Rosie R, et al. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol. 1996;16:325-344.
33. Maggi A, Perez J. Role of female gonadal hormones in the CNS: clinical and experimental aspects. Life Sci. 1985;37:893-906.
34. Genazzani AR, Lucchesi A, Stomati M, et al. Effects of sex steroid hormones on the neuroendocrine system. Eur J Contracept Reprod Health Care. 1997;2:63-69.
35. Silva I, Mor G, Naftolin F. Estrogen and the aging brain. Maturitas. 2001;38:95-100; discussion 100-101.
36. Woolley CS. Effects of estrogen in the CNS. Curr Opin Neurobiol. 1999;9:349-354.
37. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279-307.
38. Stahl SM. Sex and psychopharmacology: is natural estrogen a psychotropic drug in women? Arch Gen Psychiatry. 2001;58:537-538.
39. Halbreich U, Kahn LS. Role of estrogen in the etiology and treatment of mood disorders. CNS Drugs. 2001;15:797-817.
40. Bethea CL, Lu NZ, Gundlah C, et al. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol. 2002;23:41-100.
41. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry. 2003;160:1522-1524.
42. Garlow S, Musselman D, Nemeroff C. The neurochemistry of mood disorders: clinical studies. In: Charney D, Nestler E, Bunney B, eds. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999:348-364.
43. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci. 1990;592:52-86.
44. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol. 1994;29:319-336.
45. Joffe H, Soares CN, Cohen LS. Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin North Am. 2003;26:563-580.
46. Stearns V, Hayes DF. Approach to menopausal symptoms in women with breast cancer. Curr Treat Options Oncol. 2002;3:179-190.
47. Benshushan A, Brzezinski A. Tamoxifen effects on menopause-associated risk factors and symptoms. Obstet Gynecol Surv. 1999;54:272-278.
48. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289:2827-2834.
49. Gordon S, Walsh BW, Ciaccia AV, et al. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol. 2004;103:267-273.
50. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977;4:31-47.
51. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol. 1994;4:214-220.
52. Joffe H, Hennen J, Soares CN, et al. Hot flushes associated with depression in perimenopausal women seeking primary care. Menopause. 2002;9:392-398.
53. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: etiology and management. Drugs Aging. 2001;18:597-606.
54. Soares CN. Sex, hormones and depression: the impact of sex steroids on mood across the reproductive life cycle. Presented at: 156th American Psychiatric Association Annual Meeting; 2003; San Francisco, California.
55. Stewart AJ, Ostrove JM. Women's personality in middle age. Gender, history, and midcourse corrections. Am Psychol. 1998;53:1185-1194.
56. Notman MT. Midlife concerns of women: implications of the menopause. Am J Psychiatry. 1979;136:1270-1274.
57. Dennerstein L, Dudley E, Guthrie J. Empty nest or revolving door? A prospective study of women's quality of life in midlife during the phase of children leaving and reentering the home. Psychol Med. 2002;32:545-550.
58. Lock M, Kaufert P. Menopause, local biologies, and cultures of aging. Am J Human Biol. 2001;13:494-504.
59. Nagata C, Takatsuta N, Inaba S. Association of diet and other lifestyle with onset of menopause in Japanese women. Maturitas. 1998;29:105-113.
60. Holte A. Menopause, mood and hormone replacement therapy: methodological issues. Maturitas. 1998;29:5-18.
61. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9:393-399.
62. Pearce J, Hawton K, Blake F, et al. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res. 1997;42:177-186.
63. Coope J. Is estrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134-140.
64. George GC, Utian WH, Beaumont PJ, et al. Effect of exogenous estrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J. 1973;47:2387-2388.
65. Coppen A, Bishop M, Beard R. Effects of piperazine oestrone sulphate on plasma tryptophan, estrogens, gonadotrophins and psychological functioning in women following hysterectomy. Curr Med Res Opin. 1977;4:29-36.
66. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology (Berl). 1995;122:321-329.
67. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry. 2003;160:1519-1522.
68. Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55:406-412.
69. Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging. 2003;20:85-100.
70. Ramachandran C, Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev. 2000;42:197-223.
71. Scott RT Jr, Ross B, Anderson C, et al. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol. 1991;77:758-764.
72. Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475-484.
73. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-933.
74. Fraser I, Wang Y. New delivery systems for hormone replacement therapy. In: Studd J, ed. The Management of Menopause-Annual Review. London: Parthenon; 1998:101-110.
75. Coope J, Thomson JM, Poller L. Effects of "natural estrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J. 1975;4:139-143.
76. Strickler RC, Borth R, Cecutti A, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med. 1977;7:631-639.
77. Thompson J, Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. Br Med J. 1977;2:1317-1319.
78. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44:798-811.
79. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-850.
80. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry. 1997;5:97-106.
81. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11-17.
82. Schneider L, Small G, Clary C. Estrogen replacement therapy and antidepressant response to sertraline, Presented at: Proceedings of the Annual Meeting of the American Psychiatric Association; 1998; Toronto, Canada.
83. Cassano P, Soares CN, Cohen LS, et al. Sex and age-related differences in major depressive disorder with comorbid anxiety treate with fluoxetine. Arch Women Mental Health. 2004;7:167-171.
84. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
85. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry. 2003;64:473-479.
86. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology. 1996;21:421-430.
87. Yaffe K, Grady D, Pressman A, et al. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. [see comments] J Am Geriatr Soc. 1998;46:816-821.
88. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc. 1996;44:818-822.
89. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 1997;49:1491-1497.
90. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci. 1999;24:315-321.
91. Maki P, Zonderman A, Resnick S. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001;158:227-233.
92. LeBlanc ES, Janowsky J, Chan BK, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
93. Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58:435-440.
94. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav. 1995;29:312-321.
95. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
96. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
97. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425-432.
98. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999;22(suppl 2):S347-S353.
99. Shaver JL. Women and sleep. Nurs Clin North Am. 2002;37:707-718.
100. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA. 1981;245:1741-1744.
101. Woodward S, Freedman RR. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep. 1994;17:497-501.
102. Shaver JL, Zenk SN. Sleep disturbance in menopause. J Womens Health Gend Based Med. 2000;9:109-118.
103. Mallon L, Broman JE, Hetta J. Relationship between insomnia, depression, and mortality: a 12-year follow-up of older adults in the community. Int Psychogeriatr. 2000;12:295-306.
104. Moe KE. Reproductive hormones, aging, and sleep. Semin Reprod Endocrinol. 1999;17:339-348.
105. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199.
106. Foundation NS. 1998 Women and Sleep Poll. National Sleep Foundation; 1998. Available at: www.sleepfoundation. org/publications/1998womenpoll.cfm.
107. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162:225-233.
108. Ponciano E, Freitas F, Camara J, et al. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol. 1990;5(suppl 2):69-77.
109. Moskowitz H, Linnoila M, Roehrs T. Psychomotor performance in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 1990;10:44S-55S.
110. Kales A, Manfredi RL, Vgontzas AN, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther. 1991;49:468-476.
111. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol. 1997;20:116-125.
112. Hedner J, Yaeche R, Emilien G, et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15:704-712.
113. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26:793-799.
114. Halbreich U. Hormonal interventions with psychopharmacological potential: an overview. Psychopharmacol Bull. 1997;33:281-286.
115. Lawrie T, Hofmeyer G, de Jager M, et al. A double-blind randomised placebo-controlled trial of postnatal noethisterone enanthate: The effect of postnatal depression and serum hormones. J Obstet Gynaecol. 2000;105:1082-1090.
116. Freeman EW, Purdy RH, Coutifaris C, et al. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 1993;58:478-484.
117. Westhoff C, Wieland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception. 1995;51:351-354.
118. Wieland S, Belluzzi J, Hawkinson JE, et al. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology (Berl). 1997;134:46-54.
119. Gupta N, O'Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol. 2001;14:71-76.
120. Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception. 2000;61:385-390.
121. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev. 1999;30:264-288.
122. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153:974-984.
123. Morrison MF. Androgens in the elderly: will androgen replacement therapy improve mood, cognition, and quality of life in aging men and women. Psychopharmacol Bull. 1997;33:293-296.
124. Zumoff B, Bradlow H. Sex difference in the metabolism of dehydroisoandrosterone sulfate. J Clin Endocrinol Metab. 1980;51:334-336.
125. Davis S. The therapeutic use of androgens in women. J Steroid Biochem Mol Biol. 1999;69:177-184.
126. Archer J. The influence of testosterone on human aggression. Br J Psychol. 1991;82:1-28.
127. Christiansen K. Behavioural effects of androgen in men and women. J Endocrinol. 2001;170:39-48.
128. Shifren JL, Schiff I. The aging ovary. J Womens Health Gend Based Med. 2000;9:S3-S7.
129. Cashdan E. Hormones, sex, and status in women. Horm Behav. 1995;29:354-366.
130. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
131. Barrett-Connor E, von Muhlen D, Laughlin GA, et al. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc. 1999;47:685-691.
132. Yaffe K, Ettinger B, Pressman A, et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry. 1998;43:694-700.
133. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41:311-318.
134. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
135. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.
136. Notelovitz M. The clinical practice impact of the Women's Health Initiative: political vs biologic correctness. Maturitas. 2003;44:3-9.
137. Joffe H, Groninger H, Soares CN, et al. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gend Based Med. 2001;10:999-1004.
138. Soares CN, Arsenio HC, Bankier B, et al. Impact of escitalopram versus norethindrone acetate and ethinyl estradiol on depression, vasomotor symptoms, and quality of life in peri- and postmenopausal women: a randomized trial. Presented at: ACNP 42nd Annual Meeting; December 7-11, 2003; San Juan, Puerto Rico.
139. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059-2063.